Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 274, Issue 1-2, 2014, Pages 111-124

  Abramowski, Pierre ^a   Steinbach, Karin ^a,b   Zander, Axel R ^a   Martin, Roland ^a,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; Edelfosine; Experimental autoimmune encephalomyelitis; Multiple sclerosis; T cells

Indexed keywords

CASPASE 3; EDELFOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPH NODE; LYMPHOCYTE PROLIFERATION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN;

APOPTOSIS; EDELFOSINE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE SCLEROSIS; T CELLS;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOLOGIC FACTORS; MALE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; PHOSPHODIESTERASE INHIBITORS; PHOSPHOLIPID ETHERS; T-LYMPHOCYTES;

EID: 84906939550     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.07.007     Document Type: Article

References (69)

1. Abramowski P., Otto B., Martin R. The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response. PLoS One 2014, 9:e91970.
2. Alonso M.T., Gajate C., Mollinedo F., Modolell M., Alvarez J., García-Sancho J. Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis. Br. J. Pharmacol. 1997, 121:1364-1368.
3. Arnold B., Reuther R., Weltzien H.U. Distribution and metabolism of synthetic alkyl analogs of lysophosphatidylcholine in mice. Biochim. Biophys. Acta 1978, 530:47-55.
4. Baker D., O'Neill J.K., Amor S., Khamashta M.A., Turk J.L. Inhibition of the chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH3. Int. J. Immunopharmacol. 1991, 13:385-392.
5. Beecham A.H., Patsopoulos N.A., Xifara D.K., Davis M.F., Kemppinen A., Cotsapas C., Shah T.S., Spencer C., Booth D., Goris A., Oturai A., Saarela J., Fontaine B., Hemmer B., Martin C., Zipp F., D'Alfonso S., Martinelli-Boneschi F., Taylor B., Harbo H.F., Kockum I., Hillert J., Olsson T., Ban M., Oksenberg J.R., Hintzen R., Barcellos L.F., Agliardi C., Alfredsson L., Alizadeh M., Anderson C., Andrews R., Søndergaard H.B., Baker A., Band G., Baranzini S.E., Barizzone N., Barrett J., Bellenguez C., Bergamaschi L., Bernardinelli L., Berthele A., Biberacher V., Binder T.M.C., Blackburn H., Bomfim I.L., Brambilla P., Broadley S., Brochet B., Brundin L., Buck D., Butzkueven H., Caillier S.J., Camu W., Carpentier W., Cavalla P., Celius E.G., Coman I., Comi G., Corrado L., Cosemans L., Cournu-Rebeix I., Cree B.A.C., Cusi D., Damotte V., Defer G., Delgado S.R., Deloukas P., di Sapio A., Dilthey A.T., Donnelly P., Dubois B., Duddy M., Edkins S., Elovaara I., Esposito F., Evangelou N., Fiddes B., Field J., Franke A., Freeman C., Frohlich I.Y., Galimberti D., Gieger C., Gourraud P.-A., Graetz C., Graham A., Grummel V., Guaschino C., Hadjixenofontos A., Hakonarson H., Halfpenny C., Hall G., Hall P., Hamsten A., Harley J., Harrower T., Hawkins C., Hellenthal G., Hillier C., Hobart J., Hoshi M., Hunt S.E., Jagodic M., Jelčić I., Jochim A., Kendall B., Kermode A., Kilpatrick T., Koivisto K., Konidari I., Korn T., Kronsbein H., Langford C., Larsson M., Lathrop M., Lebrun-Frenay C., Lechner-Scott J., Lee M.H., Leone M.A., Leppä V., Liberatore G., Lie B.A., Lill C.M., Lindén M., Link J., Luessi F., Lycke J., Macciardi F., Männistö S., Manrique C.P., Martin R., Martinelli V., Mason D., Mazibrada G., McCabe C., Mero I.-L., Mescheriakova J., Moutsianas L., Myhr K.-M., Nagels G., Nicholas R., Nilsson P., Piehl F., Pirinen M., Price S.E., Quach H., Reunanen M., Robberecht W., Robertson N.P., Rodegher M., Rog D., Salvetti M., Schnetz-Boutaud N.C., Sellebjerg F., Selter R.C., Schaefer C., Shaunak S., Shen L., Shields S., Siffrin V., Slee M., Sorensen P.S., Sorosina M., Sospedra M., Spurkland A., Strange A., Sundqvist E., Thijs V., Thorpe J., Ticca A., Tienari P., van Duijn C., Visser E.M., Vucic S., Westerlind H., Wiley J.S., Wilkins A., Wilson J.F., Winkelmann J., Zajicek J., Zindler E., Haines J.L., Pericak-Vance M.A., Ivinson A.J., Stewart G., Hafler D., Hauser S.L., Compston A., McVean G., De Jager P., Sawcer S.J., McCauley J.L. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 2013, 45:1353-1360.
6. Bhamra R., Bolcsak L.E., Ahmad I., Schupsky J., Roberts P., Stevens R., Cavanaugh C., Swenson C.E. Activity, pharmacokinetics and tissue distribution of TLC ELL-12 (liposomal antitumor ether lipid) in rats with transplantable, s.c. methylnitrosourea-induced tumors. Anticancer. Drugs 2003, 14:481-486.
7. Boggs K.P., Rock C.O., Jackowski S. Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine. J. Biol. Chem. 1995, 270:11612-11618.
8. Burdzy K., Munder P.G., Fischer H., Westphal O. Increase in the phagocytosis of peritoneal macrophages by lysolecitin. Z. Naturforsch. B 1964, 19:1118-1120.
9. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37:424-435.
10. Chabannes D., Ryffel B., Borel J.F. SRI 62-834, a cyclic ether analogue of the phospholipid ET-18-OCH3 displays long-lasting beneficial effect in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Comparison with Cyclosporin and (Val2)-dihydrocyclosporin effects in. J. Autoimmun. 1992, 199-211.
11. Chignard M., Le Couedic J.P., Tence M., Vargaftig B.B., Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature 1979, 279:799-800.
12. Clement J.M., Kent C. CTP:phosphocholine cytidylyltransferase: insights into regulatory mechanisms and novel functions. Biochem. Biophys. Res. Commun. 1999, 257:643-650.
13. Coles A.J., Wing M.G., Molyneux P., Paolillo A., Davie C.M., Hale G., Miller D., Waldmann H., Compston A. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 1999, 46:296-304.
14. Das G., Sheridan S., Janeway C.A. The source of early IFN- γ that plays a role in Th1 priming. Animals 2011, 167:2004-2010.
15. Diomede L., Colotta F., Piovani B., Re F., Modest E.J., Salmona M. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int. J. Cancer 1993, 53:124-130.
16. Estella-Hermoso de Mendoza A., Campanero M.A., de la Iglesia-Vicente J., Gajate C., Mollinedo F., Blanco-Prieto M.J. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin. Cancer Res. 2009, 15:858-864.
17. Flügel A., Berkowicz T., Ritter T., Labeur M., Jenne D.E., Li Z., Ellwart J.W., Willem M., Lassmann H., Wekerle H. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001, 14:547-560.
18. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008, 7:852-858.
19. Friese M.A., Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 2005, 128:1747-1763.
20. Gajate C., Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001, 98:3860-3863.
21. Gajate C., Fonteriz R.I., Cabaner C., Alvarez-Noves G., Alvarez-Rodriguez Y., Modolell M., Mollinedo F. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int. J. Cancer 2000, 85:674-682.
22. Gajate C., Gonzalez-Camacho F., Mollinedo F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One 2009, 4:e5044.
23. Haas J., Hug A., Viehöver A., Fritzsching B., Falk C.S., Filser A., Vetter T., Milkova L., Korporal M., Fritz B., Storch-Hagenlocher B., Krammer P.H., Suri-Payer E., Wildemann B. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 2005, 35:3343-3352.
24. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
25. Hillert J., Olerup O. HLA and MS. Neurology 1993, 43:2426-2427.
26. Jersild C., Fog T., Hansen G.S., Thomsen M., Svejgaard A., Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973, 2:1221-1225.
27. Klein-Franke A., Munder P.G. Alkyllysophospholipid prevents induction of experimental allergic encephalomyelitis. J. Autoimmun. 1992, 5:83-91.
28. Kötting J., Marschner N.W., Neumüller W., Unger C., Eibl H. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog. Exp. Tumor Res. 1992, 34:131-142.
29. Kovarik J., Chabannes D., Borel J.F. Immunoregulation and drug treatment in chronic relapsing experimental allergic encephalomylitis in the Lewis rat. Int. J. Immunopharmacol. 1995, 17:255-263.
30. Linker R.A., Rott E., Hofstetter H.H., Hanke T., Toyka K.V., Gold R. EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. Neurobiol. Dis. 2005, 19:218-228.
31. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996, 86:147-157.
32. Lucchinetti C.F., Brück W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996, 6:259-274.
33. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallström E., Khademi M., Oturai A., Ryder L.P., Saarela J., Harbo H.F., Celius E.G., Salter H., Olsson T., Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007, 39:1108-1113.
34. Martin R., Jaraquemada D., Flerlage M., Richert J., Whitaker J., Long E.O., McFarlin D.E., McFarland H.F. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 1990, 145:540-548.
35. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992, 10:153-187.
36. McElroy J.P., Oksenberg J.R. Multiple sclerosis genetics. Curr. Top. Microbiol. Immunol. 2008, 318:45-72.
37. McGeachy M.J., Stephens L.A., Anderton S.M. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 2005, 175:3025-3032.
38. McRae B.L., Miller S.D. Fine specificity of CD4+ T cell responses to the dominant encephalitogenic PLP 139-151 peptide in SJL/J mice. Neurochem. Res. 1994, 19:997-1004.
39. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 1995, 182:75-85.
40. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
41. Mollinedo F., Martínez-Dalmau R., Modolell M. Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. Biochem. Biophys. Res. Commun. 1993, 192:603-609.
42. Mollinedo F., Fernández-Luna J.L., Gajate C., Martín-Martín B., Benito A., Martínez-Dalmau R., Modolell M. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res. 1997, 57:1320-1328.
43. Munder P.G., Westphal O. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem. Immunol. 1990, 49:206-235.
44. Munder P.G., Modolell M., Ferber E., Fischer H. Phospholipids in quartz-damaged macrophages. Biochem. Z. 1966, 344:310-313.
45. Munder P.G., Ferber E., Modolell M., Fischer H. The influence of various adjuvants on the metabolism of phospholipids in macrophages. Int. Arch. Allergy Appl. Immunol. 1969, 36:117-128.
46. O'Flaherty J.T., Wykle R.L., Miller C.H., Lewis J.C., Waite M., Bass D.A., McCall C.E., DeChatelet L.R. 1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. Am. J. Pathol. 1981, 103:70-78.
47. Ota K., Matsui M., Milford E.L., Mackin G.A., Weiner H.L., Hafler D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990, 346:183-187.
48. Pettinelli C.B., McFarlin D.E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J. Immunol. 1981, 127:1420-1423.
49. Raine C.S., Barnett L.B., Brown A., Behar T., McFarlin D.E. Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab. Investig. 1980, 43:150-157.
50. Read R.A., Moore E.E., Moore F.A., Carl V.S., Banerjee A. Platelet-activating factor-induced polymorphonuclear neutrophil priming independent of CD11b adhesion. Surgery 1993, 114:308-313.
51. Richert J.R., McFarlin D.E., Rose J.W., McFarland H.F., Greenstein J.I. Expansion of antigen-specific T cells from cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 1983, 5:317-324.
52. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C.A., Patsopoulos N.A., Moutsianas L., Dilthey A., Su Z., Freeman C., Hunt S.E., Edkins S., Gray E., Booth D.R., Potter S.C., Goris A., Band G., Oturai A.B., Strange A., Saarela J., Bellenguez C., Fontaine B., Gillman M., Hemmer B., Gwilliam R., Zipp F., Jayakumar A., Martin R., Leslie S., Hawkins S., Giannoulatou E., D'alfonso S., Blackburn H., Martinelli Boneschi F., Liddle J., Harbo H.F., Perez M.L., Spurkland A., Waller M.J., Mycko M.P., Ricketts M., Comabella M., Hammond N., Kockum I., McCann O.T., Ban M., Whittaker P., Kemppinen A., Weston P., Hawkins C., Widaa S., Zajicek J., Dronov S., Robertson N., Bumpstead S.J., Barcellos L.F., Ravindrarajah R., Abraham R., Alfredsson L., Ardlie K., Aubin C., Baker A., Baker K., Baranzini S.E., Bergamaschi L., Bergamaschi R., Bernstein A., Berthele A., Boggild M., Bradfield J.P., Brassat D., Broadley S.A., Buck D., Butzkueven H., Capra R., Carroll W.M., Cavalla P., Celius E.G., Cepok S., Chiavacci R., Clerget-Darpoux F., Clysters K., Comi G., Cossburn M., Cournu-Rebeix I., Cox M.B., Cozen W., Cree B.A.C., Cross A.H., Cusi D., Daly M.J., Davis E., de Bakker P.I.W., Debouverie M., D'hooghe M.B., Dixon K., Dobosi R., Dubois B., Ellinghaus D., Elovaara I., Esposito F., Fontenille C., Foote S., Franke A., Galimberti D., Ghezzi A., Glessner J., Gomez R., Gout O., Graham C., Grant S.F.A., Guerini F.R., Hakonarson H., Hall P., Hamsten A., Hartung H.-P., Heard R.N., Heath S., Hobart J., Hoshi M., Infante-Duarte C., Ingram G., Ingram W., Islam T., Jagodic M., Kabesch M., Kermode A.G., Kilpatrick T.J., Kim C., Klopp N., Koivisto K., Larsson M., Lathrop M., Lechner-Scott J.S., Leone M.A., Leppä V., Liljedahl U., Bomfim I.L., Lincoln R.R., Link J., Liu J., Lorentzen A.R., Lupoli S., Macciardi F., Mack T., Marriott M., Martinelli V., Mason D., McCauley J.L., Mentch F., Mero I.-L., Mihalova T., Montalban X., Mottershead J., Myhr K.-M., Naldi P., Ollier W., Page A., Palotie A., Pelletier J., Piccio L., Pickersgill T., Piehl F., Pobywajlo S., Quach H.L., Ramsay P.P., Reunanen M., Reynolds R., Rioux J.D., Rodegher M., Roesner S., Rubio J.P., Rückert I.-M., Salvetti M., Salvi E., Santaniello A., Schaefer C.A., Schreiber S., Schulze C., Scott R.J., Sellebjerg F., Selmaj K.W., Sexton D., Shen L., Simms-Acuna B., Skidmore S., Sleiman P.M.A., Smestad C., Sørensen P.S., Søndergaard H.B., Stankovich J., Strange R.C., Sulonen A.-M., Sundqvist E., Syvänen A.-C., Taddeo F., Taylor B., Blackwell J.M., Tienari P., Bramon E., Tourbah A., Brown M.A., Tronczynska E., Casas J.P., Tubridy N., Corvin A., Vickery J., Jankowski J., Villoslada P., Markus H.S., Wang K., Mathew C.G., Wason J., Palmer C.N.A., Wichmann H.-E., Plomin R., Willoughby E., Rautanen A., Winkelmann J., Wittig M., Trembath R.C., Yaouanq J., Viswanathan A.C., Zhang H., Wood N.W., Zuvich R., Deloukas P., Langford C., Duncanson A., Oksenberg J.R., Pericak-Vance M.A., Haines J.L., Olsson T., Hillert J., Ivinson A.J., De Jager P.L., Peltonen L., Stewart G.J., Hafler D.A., Hauser S.L., McVean G., Donnelly P., Compston A. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
53. Scaffidi C., Kirchhoff S., Krammer P.H., Peter M.E. Apoptosis signaling in lymphocytes. Curr. Opin. Immunol. 1999, 11:277-285.
54. Schmied M., Breitschopf H., Gold R., Zischler H., Rothe G., Wekerle H., Lassmann H. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol. 1993, 143:446-452.
55. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 1998, 84:238-249.
56. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
57. Tsutsumi T., Tokumura A., Kitazawa S. Undifferentiated HL-60 cells internalize an antitumor alkyl ether phospholipid more rapidly than resistant K562 cells. Biochim. Biophys. Acta 1998, 1390:73-84.
58. Van der Luit A.H., Budde M., Ruurs P., Verheij M., van Blitterswijk W.J. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J. Biol. Chem. 2002, 277:39541-39547.
59. Van Der Luit A.H., Budde M., Verheij M., Van Blitterswijk W.J. Different modes of internalization of apoptotic alkyl-lysophospholipid and cell-rescuing lysophosphatidylcholine. Biochem. J. 2003, 374:747-753.
60. Van der Luit A.H., Vink S.R., Klarenbeek J.B., Perrissoud D., Solary E., Verheij M., van Blitterswijk W.J. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol. Cancer Ther. 2007, 6:2337-2345.
61. Van der Sanden M.H.M., Houweling M., Duijsings D., Vaandrager A.B., van Golde L.M.G. Inhibition of phosphatidylcholine synthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis. Biochim. Biophys. Acta 2004, 1636:99-107.
62. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
63. Wekerle H., Linington C., Lassmann H., Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci. 1986, 8:271-277.
64. Yu P., Gregg R.K., Bell J.J., Ellis J.S., Divekar R., Lee H., Jain R., Waldner H., Hardaway J.C., Collins M., Kuchroo V.K., Zaghouani H. Functions against experimental allergic encephalomyelitis upon activation with cognate antigen 1. J. Immunol. 2005, 174:6772-6780.
65. Zamvil S.S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 1990, 8:579-621.
66. Zeine R., Owens T. Loss rather than downregulation of CD4+ T cells as a mechanism for remission from experimental allergic encephalomyelitis. J. Neuroimmunol. 1993, 44:193-198.
67. Zerp S.F., Vink S.R., Ruiter G.A., Koolwijk P., Peters E., van der Luit A.H., de Jong D., Budde M., Bartelink H., van Blitterswijk W.J., Verheij M. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents. Anticancer Drugs 2008, 19:65-75.
68. Zhang X. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int. Immunol. 2004, 16:249-256.
69. Zoeller R.A., Layne M.D., Modest E.J. Animal cell mutants unable to take up biologically active glycerophospholipids. J. Lipid Res. 1995, 36:1866-1875.